Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet
Top Cited Papers
- 1 January 2010
- journal article
- research article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 125 (1), 131-138.e7
- https://doi.org/10.1016/j.jaci.2009.10.035
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
This publication has 32 references indexed in Scilit:
- Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT studyAllergy, 2008
- Sublingual immunotherapy: what have we learnt from the ‘big trials’?Current Opinion in Allergy and Clinical Immunology, 2008
- A survey of the burden of allergic rhinitis in the USAAllergy, 2007
- Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: Case-control studyJournal of Allergy and Clinical Immunology, 2007
- Safety of a SQ‐standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo‐controlled trialAllergy, 2006
- Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six‐year follow‐up study.Clinical and Experimental Allergy, 2001
- The health economics of asthma and rhinitis. I. Assessing the economic impactJournal of Allergy and Clinical Immunology, 2001
- Clinical aspects of allergic disease: A double-blind study of the discontinuation of ragweed immunotherapyJournal of Allergy and Clinical Immunology, 1997
- Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitisClinical and Experimental Allergy, 1991
- Does the effect of immunotherapy last after termination of treatment?Allergy, 1988